Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

NCT06959108 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pucotenlimab
DRUG: MRG003

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou

Collaborators

[object Object]